I visited the new Center for Cancer Immunotherapy & Immunobiology in January & April (in the pic, Sidonia Fagarasan & Masaki Tajima are walking through the still empty lab space). Cant wait to see it fully occupied & operational this November! #Immunologywww.ccii.med.kyoto-u.ac.jp/en/research/

'Of note, PD-L1 expression did not positively correlate with TMB in any of these studies, indicating that the two biomarkers are largely independent both in patients with NSCLC and with other cancers' #Immunology#Immunotherapy#Immunoskywww.nature.com/articles/s41...

Tumour mutational burden: clinical utility, challenges and emerging improvements - Nature Reviews Clinical Oncology

Tumour mutational burden (TMB), reflecting the number of mutations present in the DNA of a tumour, is a biologically appealing biomarker of a response to immune-checkpoint inhibitors (ICIs). Nonethele...

'Single-cell multiomics of myeloma treated with BCMA-targeted #CARTcells#Immunology#Immunotherapy

Deciphering the response to BCMA CAR T cell therapy - Nature Cancer

Despite the promise of chimeric antigen receptor (CAR) T cell therapy, predicting patient response is challenging. Single-cell multiomics of myeloma treated with B cell maturation antigen (BCMA)-targe...

Tumor Microenvironment Activated Cu Crosslinked Near‐Infrared Sonosensitizers for Visualized Cuproptosis‐Enhanced Sonodynamic Cancer Immunotherapy

Tumor microenvironment governs the prognostic landscape of immunotherapy for head and neck squamous cell carcinoma: A computational model-guided analysis www.biorxiv.org/content/10.1101/2024.09.26.615149v1

Tumor microenvironment governs the prognostic landscape of immunotherapy for head and neck squamous cell carcinoma: A computational model-guided analysis https://www.biorxiv.org/content/10.1101/2024.09.26.615149v1

Immune checkpoint inhibition (ICI) has emerged as a critical treatment strategy for squamous cell ca

Immunotherapy but for Blake’s posting

C-Life Cubic-Cell-Culture CBM-Cell-Bank-Medculture IUI-Individual-Universal-Immunotherapy Replicate-Ex-Vivo-In-Vivo-Proven-Process Ex-Vivo-Ideal-Space-Time-Quantity-Type-Cells-Proteins Ex-Vivo-Proven-Pathogen-Elimination-Replicated-In-Vivo http://www.mesistem.com/mesistem_061.htm

I’ll hope it works for you! I don’t have a rare type of cancer but I have a very rare/they are openly studying me way that the cancer is…going? I’m also apparently after some weird brain damage allergic to immunotherapy so there aren’t…many options. I’m glad it helps others though!

I know someone on experimental immunotherapy treatment, and it's working. May it work for you as well!💐

From standardizing cancer immunotherapy biomarkers to pushing drug companies on compassionate use, when FDA's Rick Pazdur speaks the oncology space should pay attention: pink.citeline.com/PS155298/Paz...

Pazdur Calls For 'Kumbaya’ To Standardize ImmunoOncology Biomarkers

<p>The US FDA Oncology Center of Excellence head also urged companies to commit to offer their PD-L1 drugs to certain patients free of charge via compassionate use if the gastric and esophageal cancer...